Charles River Laboratories (CRL)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 3,461,500 3,782,270 3,722,730 3,640,440 3,596,880 3,305,990 3,251,700 3,108,600 2,976,290 2,626,850 2,647,710 2,610,180 2,534,820 2,426,570 2,318,440 2,183,930 2,114,600 1,896,940 1,752,640 1,651,980
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $3,461,500K
= 0.00

The debt-to-equity ratio of Charles River Laboratories has consistently remained at 0.00 across all the reported financial periods from March 31, 2020, to December 31, 2024. This implies that the company has not utilized any debt to finance its operations or investments during this period. A debt-to-equity ratio of 0.00 indicates that the company has relied solely on equity financing, which can be considered a positive indicator of financial stability and lower financial risk. It suggests that Charles River Laboratories has a strong financial position and has not accumulated any significant debt obligations relative to its equity. A consistent zero debt-to-equity ratio may reflect a conservative financial strategy or a lack of opportunities or needs to leverage debt in its capital structure.